What is the clinical evidence from this study?

Study design: Cohort. Population: Acute lymphoblastic leukaemia (n=838). Intervention: CNS involvement at diagnosis vs. No CNS involvement at diagnosis. Primary outcome: CNS relapse in B-cell ALL (HR 4.52, 95% CI 1.35-15.2).

What does this research mean for the field?

In adult acute lymphoblastic leukaemia, central nervous system involvement at diagnosis significantly increases the risk of CNS relapse in B-cell ALL but not T-cell ALL, while overall CNS relapse is independently associated with male sex and high white blood cell counts. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

June 3, 2026British Journal of HaematologyOpen Access

Central nervous system involvement and relapse in adult acute lymphoblastic leukaemia—a population‐based analysis in 2007–2022

View Full Paper

Ask AI

Bookmark

Key result

CNS involvement at diagnosis linked to ~352% greater CNS relapse risk in adult B-cell ALL.

HR 4.52
95% CI 1.35-15.2
n=838

Why the study?

Central nervous system involvement and relapse remain a clinical challenge in acute lymphoblastic leukaemia management, but studies in adult patients are scarce.

Population

838 adult ALL patients in Sweden between 2007 and 2022

Comparison

Factors associated with CNS involvement and relapse

Design

Population-based registry cohort study

Authors

EBErik BobergKarolinska University Hospital ALAnna LübkingSkåne University Hospital ELEmma Bergfelt LennmyrUppsala University

Discussion

Member takes

Implication

May identify B-ALL patients for enhanced CNS surveillance; leaves open whether intensified prophylaxis improves outcomes in trials.

Key Points

The aim is to evaluate the factors associated with central nervous system involvement and relapse in adult acute lymphoblastic leukaemia patients in Sweden from 2007-2022.
Analyzed data from 838 adult ALL patients in Sweden between 2007 and 2022.
Evaluated association between CNS involvement and relapse with factors like white blood cell count and sex.
Calculated 5-year cumulative incidence for CNS relapse and overall survival rates.
CNS involvement at diagnosis was found in 7.8% of patients, mainly in T-cell ALL with WBC count >30 × 10⁹/L.
5-year cumulative incidence of CNS relapse was 4.6% and linked to WBC count >100 × 10⁹/L and male sex.
Patients with CNS relapse had a 2-year overall survival rate of 34%, dropping to 13% if relapse occurred within 12 months.

Study Design

Type

Cohort (n=838)

Multicenter

Yes

Structured PICO

Population

838 adult patients with acute lymphoblastic leukaemia from a Swedish population-based register between 2007 and 2022, evaluated for CNS involvement and relapse.

Outcome

Central nervous system (CNS) involvement at diagnosis and CNS relapsehard clinical

Main Result

Hazard Ratio: 4.52 (95% CI 1.35–15.2)

Contemporary treatment protocols prevent CNS relapse for most adult ALL patients, but B-ALL patients with CNS involvement at diagnosis have a high rate of CNS relapse and may require improved CNS-directed therapy.

Cite This Study

Boberg et al. (2026) conducted a cohort in Acute lymphoblastic leukaemia (n=838). CNS involvement at diagnosis vs. No CNS involvement at diagnosis was evaluated on CNS relapse in B-cell ALL (HR 4.52, 95% CI 1.35-15.2). CNS involvement at diagnosis significantly increased the rate of CNS relapse in adult patients with B-cell acute lymphoblastic leukaemia (HR 4.52; 95% CI 1.35-15.2).

synapsesocial.com/papers/6a1fc4e4dee9eb8c0dce65a2 https://doi.org/10.1111/bjh.70589

View Full Paper

Ask AI

Bookmark

June 3, 2026British Journal of HaematologyOpen Access

Central nervous system involvement and relapse in adult acute lymphoblastic leukaemia—a population‐based analysis in 2007–2022

View Full Paper

Ask AI

Bookmark

Key result

CNS involvement at diagnosis linked to ~352% greater CNS relapse risk in adult B-cell ALL.

HR 4.52
95% CI 1.35-15.2
n=838

Why the study?

Central nervous system involvement and relapse remain a clinical challenge in acute lymphoblastic leukaemia management, but studies in adult patients are scarce.

Population

838 adult ALL patients in Sweden between 2007 and 2022

Comparison

Factors associated with CNS involvement and relapse

Design

Population-based registry cohort study

Authors

EBErik BobergKarolinska University Hospital ALAnna LübkingSkåne University Hospital ELEmma Bergfelt LennmyrUppsala University

Discussion

Member takes

Implication

May identify B-ALL patients for enhanced CNS surveillance; leaves open whether intensified prophylaxis improves outcomes in trials.

Key Points

The aim is to evaluate the factors associated with central nervous system involvement and relapse in adult acute lymphoblastic leukaemia patients in Sweden from 2007-2022.
Analyzed data from 838 adult ALL patients in Sweden between 2007 and 2022.
Evaluated association between CNS involvement and relapse with factors like white blood cell count and sex.
Calculated 5-year cumulative incidence for CNS relapse and overall survival rates.
CNS involvement at diagnosis was found in 7.8% of patients, mainly in T-cell ALL with WBC count >30 × 10⁹/L.
5-year cumulative incidence of CNS relapse was 4.6% and linked to WBC count >100 × 10⁹/L and male sex.
Patients with CNS relapse had a 2-year overall survival rate of 34%, dropping to 13% if relapse occurred within 12 months.

Study Design

Type

Cohort (n=838)

Multicenter

Yes

Structured PICO

Population

838 adult patients with acute lymphoblastic leukaemia from a Swedish population-based register between 2007 and 2022, evaluated for CNS involvement and relapse.

Outcome

Central nervous system (CNS) involvement at diagnosis and CNS relapsehard clinical

Main Result

Hazard Ratio: 4.52 (95% CI 1.35–15.2)

Cite This Study

synapsesocial.com/papers/6a1fc4e4dee9eb8c0dce65a2 https://doi.org/10.1111/bjh.70589

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark